RNA Oligomers for Selective Gene Expression Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for RNA-directed methylation in mammalian cells have shown limited success in silencing gene expression, with inconsistent results and often requiring additional components like methylation inhibitors or nuclear localization peptides, and there is a need for a more potent and efficient way to modulate gene transcription.
Innovation Solution
The use of synthetic double-stranded RNA oligomers, 12-28 bases in length, complementary to specific regions around the transcription start site of target genes, such as MVP, E-cadherin, hPR, p53, and PTEN, to selectively increase or decrease gene expression without relying on DNA methylation or viral transduction, utilizing chemical modifications for stability and delivery via cationic lipids or other carriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA-directed DNA methylation is used to silence gene expression in mammalian cells, then gene silencing is achieved, but the method shows limited success with inconsistent results and often requires additional components like methylation inhibitors or nuclear localization peptides
Solution Approach 1:
The patent extracts and eliminates the requirement for DNA methylation from the gene silencing process. Instead of using RNA-directed DNA methylation pathways that require multiple additional components (methylation inhibitors, nuclear localization peptides), the invention directly targets and processes RNA molecules to achieve silencing, thereby simplifying the overall method while improving reliability
Solution Approach 2:
The patent introduces small interfering RNA (siRNA) molecules as intermediaries that directly mediate gene silencing without requiring DNA methylation. These siRNA molecules serve as the primary active component, binding to target mRNA and facilitating degradation or translational repression, thus eliminating the need for complex methylation machinery and additional chemical modifiers
2Ease of operation
If standard transfection procedures are used to deliver oligomers, then delivery is simplified, but transfection efficiency and cellular uptake may be insufficient
Solution Approach 1:
The patent employs chemically modified oligomer structures that combine RNA sequences with modified backbones or attached functional groups. These composite molecular structures enhance cellular uptake and stability while maintaining compatibility with standard transfection procedures, thus improving productivity without sacrificing ease of operation
Solution Approach 2:
The patent modifies physical and chemical parameters of the oligomer molecules, including charge distribution, hydrophobicity, and molecular size, to optimize cellular penetration. These parameter changes enable efficient delivery through standard transfection methods while significantly improving transfection efficiency and reducing required doses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves significant, specific, and efficient modulation of gene expression, with at least a 2-fold increase in target transcript synthesis, applicable across various genes and cell types, without the need for methylation or viral transduction, demonstrating robustness and versatility in gene activation and silencing.
Implementation Method 1
double-stranded RNA oligomers, 12-28 bases in length, complementary to specific regions around the transcription start site
Implementation Method 2
delivery via cationic lipids or other carriers
Data Source
AI summary
Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.